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Annexin V-DM1 is a protein-drug conjugate that is designed to deliver the 
covalently linked DM1 cytotoxic payload to tumor cells. The drug is a potent 
microtubule inhibitor that has been shown to have profound antineoplastic activity 
at extremely low concentrations by causing mitotic arrest and subsequent 
apoptosis. The protein binds with high specificity to phosphatidylserine, a 
phospholipid internally expressed on most healthy cells that is expressed 
externally in tumor cells. The conjugate was synthesized using a non-cleavable 
linker and characterized. The average drug to protein ratio was found to be 8. The 
cytotoxic activity was investigated in vitro using three breast cancer and two 
leukemia cell lines. The EC50 for EMT6 cells was 0.21 nM for the AV-DM1 
conjugate, an increase in effectivity of 130x when compared to unconjugated 
DM1; for 4T1 cells the EC50 was 0.85 nM, an increase in effectivity of 377x; for 
MCF7 cells the EC50 was 0.52 nM, an increase in effectivity of 910x; for P388 
cells the EC50 was 1.2 nM for the AV-DM1 conjugate, an increase in effectivity 









Human cancers are the result of a handful of mutations that randomly occur out of 
hundreds and potentially thousands of proto-oncogenes. The specific molecular 
phenotypes of these tumors make nearly all patients’ cancers unique in clinically 
profound ways. However, all cancers by their nature share some common 
attributes such as unbounded growth and proliferation, failure to undergo 
apoptosis, signaling for angiogenesis, and eventual metastasis [1]. 
 
Uncontrolled growth of tumors is usually due to a reduction in or even silencing 
of key growth suppression genes or growth factor receptor genes like EGFR. 
However, uncontrolled proliferation can’t be sustained indefinitely due to 
telomere shortening in normal cells. In order to be capable of truly unbounded 
growth, cancerous cells must have some way to upregulate telomerase activity to 
avoid eventual apoptosis. Another essential factor to the formation of 
macroscopic solid tumors is angiogenesis. Promotion of increased vascularity to 
the tumor microenvironment is crucial to maintaining growth as the tumor 
margins expand [2-5] 
 
Tumor metastasis is by far the main cause of mortality from cancer. It requires 
several things to occur but mainly involves a physical translocation of tumor cells 
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through the blood to a distant location and adaptation of the tumor cells to grow in 
the new microenvironment. Preparing to migrate is not a trivial task for cancer 
cells, however. The cells must first shift to a semi-pluripotent state where they can 
reduce proliferation temporarily, exchange receptors that promote cell-cell 
binding for receptors that encourage cell movement, and secrete proteases to 
degrade the local extracellular matrix and allow the exit, then the cells must 
reverse all of those changes to return to a principally proliferative state in their 
new location. Many of the factors surrounding how fast growing and easily 
metastasizing a particular tumor is are influenced by the tissue type from which 
the cancer originated. This thesis will focus on metastatic breast cancer as well as 






Among all the many and varied biomarkers of cancers, phosphatidylserine (PS) is 
one of the most ubiquitous, present in nearly all types of cancers including 
lymphoma, leukemia, lung carcinoma, colorectal carcinoma, melanoma, bladder 
carcinoma, and breast carcinoma [8]. 
 
Comprising up to 15% of the lipid bilayer, PS is expressed in all mammalian 
plasma membranes, though it is found only on the inner leaflet in the vast 
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majority of healthy cells. This asymmetry in PS expression is believed to be 
maintained by a highly selective magnesium and ATP dependent translocase 
enzyme. Under many conditions representative of both healthy and stressed cells 
such as aging, migration, viral infection, and most commonly apoptosis, the 
phospholipid distribution of the membrane is disrupted by a combination of 
translocase inhibition and calcium dependent phospholipid scramblase 
upregulation [9-12]. 
 
Once expressed, PS plays multiple signaling roles for the immune system. 
Apoptosis is a mechanism for cell death and debris clearance that avoids an 
inflammatory response from T and B cells. PS on apoptotic cells is a ligand for 
macrophages, promoting the migration to and engulfing of the stressed cell by the 
macrophage. However, tumor cells, especially tumor endothelium, have adopted 
this false-apoptotic signaling to avoid further investigation by the immune system. 
While expressing PS that encourages macrophagic endocytosis, they also express 
surface proteins such as CD47 and CD31 which discourage macrophages from 
interacting with healthy cells, resulting in pathogenic tissue that pacifies 
phagocytic cells while suppressing recognition by other immune cell populations 
[13, 14]. 
 
When tumors grow to be greater than 2 mm they must promote a high degree of 
vascularization to supply sufficient oxygen to the tumor tissue for sustained 
growth resulting in sprawling and disorganized endothelium overexpressing PS in 
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macroscopic tumors [15, 16]. Tumor vasculature forms in a rapid and random 
manner. The immature endothelium fails to make the same tight cell-cell 
junctions found in regular blood vessels; where normal endothelium is essentially 
impermeable to particles greater than 2 nm, the spaces between cells in tumor 
vasculature can range from just a few nanometers to micrometer or larger gaps, 
greatly increasing the permeability and penetration of particles into the tumor 
tissue. The disorganized nature of tumor vasculature has been well documented as 
the enhanced permeability and retention (EPR) effect [17, 18]. This combination 




Annexin V (AV) is a protein from a family of calcium-dependent, membrane-
binding proteins. In the body naturally, it acts as a powerful anticoagulant, coating 
cell surfaces and preventing membrane-membrane adhesions. It is comprised of 
an amphipathic monomer that contains four domains that create a central 
convexity that strongly associates with phosphatidylserine exposed on the surface 
of cells in the presence of calcium (KD < .2 nM). It is suspected that the presence 
of zinc can increase the affinity of AV for PS [19, 20]. 
 
AV is a monomer in solution, but it has the ability to form trimer crystals with 
other AV proteins through associations between domain one of one protein and 
domain three of another. These trimers can also associate with other trimers, 
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creating a two dimensional lattice of the surface of cells. This puts pressure on the 
cell membrane as the lattice retains the convex shape of the individual AV 
monomers, inducing endocytosis of the PS-expressing/AV-bound portions of the 
cell membrane as shown in Figure 1 [21, 22]. 
 








In December of 1971, President Nixon signed into law the National Cancer Act, 
declaring a “war on cancer”. This act empowered the National Cancer Institute 
and appropriated hundreds of millions of dollars over the next few years to 
establish the first 15 national cancer centers around the country and support 
research to “conquer cancer” [23, 24]. 
 
One of the immediate products of this unprecedented initiative was the discovery 
of a class of molecules termed “maytansinoids”. In 1972, Kupchan published the 
first paper describing the isolation, structure, and antileukemic activity of what he 
called an “ansa macrolide” from the Maytenus serrata plant, a short, shrub-like 
tree from central Africa [25, 26]. Kupchan expanded upon his findings two years 
later, describing four more maytansinoid derivatives and their profound activity 
against B16 melanoma and lung carcinoma cell lines [27]. 
 
By 1975, other labs had begun to take an interest in the antineoplastic potential of 
the maytansinoids, and the mechanism of action had begun to be elucidated. M 
phase mitotic arrest and cross-resistance to vinca alkaloids were indicative of 
microtubule inhibition [28-30]. By 1978, the first Phase 1 clinical trials of 
maytansine had shown fantastic results with leukemia, with several patients going 
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into complete remission and patients that had been treated with and were resistant 
to vincristine, another microtubule inhibiting agent, showed marked 
improvement. Trials with breast cancer and melanoma were not as encouraging. 
Unfortunately, maytansine showed significant gastrointestinal and central nervous 
system toxicity. Severe vomiting and diarrhea were nearly universal reactions to 
the drug; lethargy, weakness, and insomnia were also commonly reported. The 
combination of these adverse toxicities resulted in some patients refusing to 
continue treatment with maytansine [31-33]. 
 
Most of the excitement surrounding maytansinoids had passed by the early 1980s 
due to disappointing therapeutic results at the maximal tolerated doses in clinical 
trials which was only around 1 mg/m2 [34]. With the advent of humanized 
monoclonal antibodies in 1988 and the subsequent flurry of research surrounding 
immunoconjugates, maytansinoids were given a second look by Goldmacher. In 
order to increase the therapeutic index of highly potent drugs like maytansine, he 
began make modifications to the molecule to make it easier to link to monoclonal 
antibodies. The first of the modifications was to introduce a sulfhydryl group to 
the molecule in order to allow a disulfide bridge to be made between drug and 
protein. This modified maytansinoid became known as “drug maytansinoid-1” or 
DM1, which showed 3-10x more antitumor activity than maytansine. Clinical 
trials on antibody conjugated maytansinoids began as early as 2002 with 
antibodies like anti-NCAM1 and cantuzumab for colorectal, pancreatic, lung and 
myeloma cancers, TA.1-DM1 for HER2+ breast cancer, C242-DM1 for colorectal 
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and pancreatic, N901-DM1 for small cell lung cancer, and J591-DM1 for prostate 
cancer [35]. 
 
These trials as well as pre-clinical work showed maximal tolerated weekly doses 
of 115 mg/m2, over 100 times the dose possible with the unconjugated drug, and 
reduced toxicity by 1000 times to non-antigen presenting cells [36-38]. Since 
then, much more work has been done in characterizing and elucidating the 
specific mechanisms of maytansine derivative conjugates. In 2013, trastuzumab-
DM1, trade name Kadcyla, was the third ever antibody drug conjugate to receive 
FDA approval in the United States. It is approved to treat HER2 positive 
metastatic breast cancers and is undergoing more clinical trials to investigate 
possible drug combinations [39]. Other drugs currently in clinical trials include 
lorvotuzumab mertansine for recurrent neuroblastomas and bivatuzumab 
mertansine for CD44v6 positive breast cancer [40, 41]. 
 
Mechanism of Action 
 
Mertansine (drug maytansinoid 1, DM1) is a microtubule inhibiting agent with an 
easily accessible sulfhydryl group which can be conjugated to proteins in a variety 
of both cleavable and non-cleavable linkages. Its structure is shown in Figure 2.  
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Figure 2. Mertansine Chemical Structure, Formula: C35H48ClN3O10S [42]. 
 
It has a molecular weight of 738.3 Da. It is sparingly soluble in aqueous solutions 
and is soluble in DMSO up to about 10 mM [43]. It was originally thought that 
maytansinoids acted on the same site on tubulin as vinca alkaloids because they 
appear to competitively inhibit each other and binding is mutually exclusive. It is 
now suspected that mertansine binds to tubulin in a distinct site entirely on the 
beta-tubulin domain preventing longitudinal microtubule assembly in contrast to 
vinblastine and the other vinca alkaloids that bind in between the alpha- and beta-
tubulin heterodimers, acting as a sort of wedge, causing useless curved 
microtubules to form as shown in Figure 3. Regardless of the separate binding 
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sites, the formation of one drug-tubulin complex causes the occlusion of the other 
site. Mertansine’s dissociation constant (KD) for beta-tubulin is about 1 uM, a 20x 
stronger affinity for binding sites than vinblastine [44-46]. 
 
Figure 3. Mertansine tubulin binding interaction and inhibition [47]. Step 1 
indicates uninhibited microtubule polymerization, 2a and b show the binding site 
and the resulting crooked microtubules of vinca alkaloids. 3a and b show the 
maytansinoid binding site and inhibition of longitudinal polymerization. 
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Microtubule inhibition results in metaphase mitotic arrest as the mitotic spindle is 
unable to attach to all chromosomes in order to pull them apart. Prolonged time in 
mitotic arrest generally results in DNA damage, apoptosis, and unviable daughter 
cells with unusual numbers of chromosomes due to a failure of spindle 
segregation. As the cell remains in metaphase, cyclin B1 phosphorylates the anti-
apoptotic protein Mcl-1 leading to its degradation and the upregulation of caspase 
enzymes that begin to attack critical cell components. Mitosis also exposes the 
telomeres of the chromosomes to damage from caspase and cytosolic DNases 
causing a strong DNA damage reaction from the cell, further upregulating 
apoptotic enzymes and cofactors [48]. 
 
Cleavable linkers like N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) 
generally form a reducible disulfide bond between the protein and the drug. In 
extracellular environments, the disulfide bond is stable and the drug is not 
released, but the intracellular environment is much more easily reduces the 
disulfide bond, releasing the drug once it has been internalized. Non-cleavable 
linkers like succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
(SMCC) require digestion by lysosomes in the cell before the drug is released. A 
structural comparison of cleavable vs. non-cleavable linkers can be found in 
Figure 4. Metabolites of the non-cleavable linker and drug combination mAb-
SMCC-DM1 have shown to be at least as effective as the parent molecule, the 
vast majority of which are S-Methyl-DM1 and lysine-SMCC-DM1 [49-51]. Now 
that drug conjugates are possible, DM1 makes an exceptionally attractive and 
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potent option for antibody linkages with its solitary thiol group. An amine-to-
sulfhydryl crosslinker like sulfo-SMCC could easily link the active drug 
molecules to lysine residues in AV. 
 
Figure 4. Different linkers allow different types of cleavage chemistry. Thioether 
linkages require digestion by proteases in lysosomes. Disulfide linkages may be 
reduced in the intracellular space, but remain stable in the plasma [52]. 
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Scope of Thesis 
 
Traditional chemotherapies are limited by wide ranging adverse effects on various 
unintended targets such as the nervous system, immune system, and 
gastrointestinal tract. Efficacy of these drugs is throttled by the need to reduce 
their systemic toxicity by lowering the overall dose. Antibody-drug conjugates 
attempt to overcome this obstacle by providing a vehicle to circulate in the plasma 
that will only release the active drug molecules once they are bound to tumor 
specific antigens. However, antibody-drug conjugates can be vulnerable to rapidly 
changing tumor phenotypes and low antigen expression in most tumor strains. 
This narrows the utility of these conjugates by increasing the cost of these 
treatments while reducing their applicability. 
 
This thesis is focused on the synthesis, characterization, and preliminary 
evaluation of the antineoplastic activity of a small protein-drug conjugate that 
targets a ubiquitous and specific marker of tumor vasculature with a non-
cleavably linked, highly potent drug molecule to maximize tumor inhibition while 








The pET-30 Ek/LIC/ANXA5 plasmid was constructed and sequenced by 
Oklahoma Medical Research Foundation as previously described [53]. 
The 5 mL HisTrap chromatography column was purchased from GE (Boston, 
MA). HRV 3C protease was purchased from Novagen (Madison, WI). Bradford 
reagent, SDS-PAGE gels, Imperial stain, and Alamar blue dye were purchased 
from Bio-Rad (Hercules, CA). Sulfo-SMCC was purchased from Sigma-Aldrich 
(St Louis, MO). 10 kDa dialysis tubing and DMSO were purchased from Thermo 
Fisher Scientific (Waltham, MA). Mertansine (DM1) and Live-Dead stain were 
purchased from Abcam (Cambridge, UK). L1210, P388, EMT6, 4T1, and MCF7 
cell lines were purchased from ATCC (Manassas, VA). FBS was purchased from 
Atlanta Biologicals (Lawrenceville, GA)  Penicillin/streptomycin was purchased 















Recombinant annexin V was produced was previously described [53]. In brief, E. 
coli harboring the plasmid containing pET-30 Ek/LIC/ANXA5 were incubated 
overnight in 100 mL of LB medium with kanamycin. The culture was added to 1 
L of fresh LB medium and incubated until the OD of the solution was at 0.5. 
Protein expression was then induced by adding isopropyl-D-
thiogalactopyranoside (IPTG) to the medium and the culture was left to incubate a 
further 6 hours. The AV expressing bacteria were centrifuged, collected, and 
sonicated to lyse the cells. The lysate containing all the cellular proteins including 
the AV protein with an N-terminal six histidine tail was centrifuged and the 
debris-free supernatant was collected. The supernatant was put through a nickel 
HisTrap column and was eluted with a 500 mM imidazole buffer. After dialysis 
the His-tagged protein was cleaved with the HRV 3C protease and purified again 
on the HisTrap column and dialyzed against a 20 mM sodium phosphate buffer a 
final time before being flash frozen in liquid nitrogen. The purified protein was 






Dissolve 1.2 milligrams of sulfo-SMCC in 200 uL of DI water; this is a 100x 
molar ratio to 1 mg/mL AV, and about a 10x molar ratio for the available lysine 
residues on AV. All of the sulfo-SMCC solution is added to 1 mg of AV and 
allowed to react at 4º C for 1 hour. The reacted solution was then dialyzed 
overnight at 4 ºC with a membrane molecular weight cutoff (MWCO) of 10 kDa 
against phosphate buffered saline (PBS), pH 7.4.  
DM1 (1.0 mg) was dissolved in 150 uL of DMSO; this is a 50x molar ratio to 1 
mg/mL annexin, the degree of sulfo-SMCC conjugation determines the number of 
available maleimide reaction sites. All of the DM1 solution was added to the 
prepared and dialyzed AV-SMCC conjugate and allowed to react at 4 ºC for 2 
hours. The reacted conjugate was dialyzed overnight at 4 ºC with a membrane 
MWCO of 10 kDa against PBS, pH 7.4.  
A Bradford assay was used to determine the final protein concentration. And the 
extent of DM1 conjugation was determined by reading absorbance at 288 nm of 
the conjugate and a blank of unconjugated AV at the same protein concentration 
and comparing to a standard curve. Figure 5 shows the major steps in the reaction.  
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The conjugate was characterized in several ways: SDS-PAGE, absorbance 




In order to confirm protein modification and estimate the drug loading of the AV 
protein, 4-20% 10-well gradient gels were purchased and used with 2x Laemmli 
sample buffer and tris-glycine-SDS running buffer (TGS). The protein and 
conjugate were each first denatured by the addition of 2.5% 2-mercaptoethanol 
and heating at 100 ºC for 5 minutes. The samples were run at 200 volts for 25 




To determine the average number of DM1 molecules per AV protein, the 
absorbance of the a sample of the conjugate and a sample of the same 
concentration of unconjugated annexin were measured at 288 nm (DM1 peak 
absorbance). The peaks were subtracted from each other, to find the contribution 
of only DM1 to the absorbance at 288 nm. The resulting absorbance value was 
compared to a standard curve of DM1 concentrations in solution to determine the 
concentration of DM1 on the proteins. The molar concentration of DM1 was 
 19 
divided by the molar concentration of the AV protein to arrive at the average 




Mass spectroscopy was attempted on the conjugate to get high-resolution data on 
the distribution of the drug-protein ratios, however the conjugate was too 
hydrophobic to be used in the mass spectroscopy formulated buffer. As a result, 
the conjugate precipitated out of solution, and no meaningful data could be 
collected by mass spectroscopy. 
 




To analyze the in vitro toxicity of the AV-DM1 conjugate compared to 
unconjugated DM1 in leukemia, two murine leukemia cell lines were used: L1210 
and P388. The cells were removed from cryopreservation and cultured in DMEM 
medium supplemented with 10% FBS and 1% penicillin/streptomycin (Pen/Strep) 
incubated at 37 ºC and 5% CO2 until one million cells of each strain were ready to 
be seeded into two 48-well plates, one for each strain. The cells were seeded at a 
density of 20,000 cells per 500 uL of DMEM medium per well and incubated for 
24 hours to allow the cells to return to a proliferative state. The wells were treated 
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in quadruplicate groups with 6 concentrations of both the AV-DM1 conjugate and 
unconjugated DM1. The AV-DM1 treatment concentrations were from 1 pM to 
0.1 uM, and the unconjugated DM1 treatment concentrations were from 1 nM to 
10 uM. A control plate with untreated cell controls and no-cell blanks was also 
prepared. The control and treated plates were incubated for 72-hours at 37ºC and 
5% CO2.  
 
After incubation, 20 uL of alamar blue was added to every plate to a final 
concentration of 10% in each well. The plates were incubated with alamar blue 
for 2 hours at 37ºC and 5% CO2 and analyzed in a plate reader using fluorescence 
with 530 nm excitation and 590 nm emission. The viability was determined by 
subtracting the no-cell blank from the untreated cell control and treated 
experimental plates then dividing the average fluorescence of the treated 













To analyze the in vitro toxicity of the AV-DM1 conjugate compared to 
unconjugated DM1 in breast cancer, three cell lines were used: EMT6 and 4T1 
murine breast cancers and MCF7 human breast cancer. Culture medium used for 
each cell line was different. The medium for EMT6 was Waymouth’s medium 
with 15% FBS, 1% Pen/Strep, for 4T1 was RPMI-1640 with 10% FBS, 1% 
Pen/Strep; for MCF7 it was EMEM 10% FBS, 1% Pen/Strep. The cells were 
removed from cryopreservation and cultured in the appropriate medium and 
incubated at 37 ºC and 5% CO2 until one million cells of each strain were ready to 
be seeded into two 96-well plates, one for each strain.  
 
The cells were seeded at a density of 12,000 cells per 200 uL of culture medium 
per well and incubated for 24 hours to allow the cells to return to a proliferative 
state. The medium was aspirated and replaced with treated media in sextuplicate 
groups with eight concentrations of both the AV-DM1 conjugate and 
unconjugated DM1. The AV-DM1 treatment concentrations were from 0.1 pM to 
1 uM, and the unconjugated DM1 treatment concentrations were from 10 pM to  
100 uM. A control plate with untreated cell controls and no-cell blanks was also 
prepared. The control and treated plates were incubated for 72 hours at 37ºC and 
5% CO2.  
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After incubation, the treatment media was aspirated and fresh media with 20 uL 
of alamar blue was added to every plate to a final concentration of 10% in each 
well. The plates were incubated with alamar blue for 2 hours at 37ºC and 5% CO2 
and analyzed in a plate reader using fluorescence with 530 nm excitation and 590 
nm emission. The viability was determined by subtracting the no-cell blank from 
the untreated cell control and treated experimental plates then dividing the 
average fluorescence of the treated experimental groups by the average of the 




Live-Dead Stain and Brightfield Images 
 
A fluorescent live-dead stain was used to image P388 cells grown in DMEM 
media supplemented with 10% FBS and 1% Pen/Strep to about one million total 
cells. The cell suspension was split, half in one tube and half in another and 
centrifuged at 1100 RCF for 5 minutes, and the supernatant was removed from 
each tube. The cell pellet in one tube was resuspended in normal DMEM media; 
the pellet in the other tube was resuspended in DMEM media with 2 mM EDTA 
in order to chelate the calcium ions and prevent the calcium dependent binding of 
AV to PS. The resuspended cells were plated at 200,000 cells per well in a 24-
well plate, and treatment with 1 nM AV-DM1 conjugate began immediately. The 
treated cells were incubated at 37º C and 5% CO2 for 3 hours. Brightfield 
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microscope pictures of the cells were taken at 10x magnification and cells were 
then stained with the Live-Dead stain for 10 minutes and fluorescence microscope 
pictures were taken at 10x magnification. Image composites were made in 
ImageJ.  
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The conjugation protocol described has been performed several times with 
average yields of about 1 mg of AV-DM1 conjugate with an average drug-protein 
ratio of about 8. The DM1 standard curve was made by serial dilutions of DM1 in 
DMSO with a DMSO blank. At high concentrations (< 1 mM ), the peak 
absorbance of DM1 is shifted higher to 294 nm and gradually shifts lower to 




Figure 6. DM1 absorption spectra from 260-310 nm over a range of 
concentrations from 11 uM to 5.6 mM. The peak absorbance shifts from 294 nm 
at the highest concentration to 288 nm at the lower concentrations 
 
The standard curve for DM1 in DMSO was determined by taking the absorption 
values at 288 nm from the above data only until 0.7 mM. Values past 0.7 mM 
ceased to have a linear relationship between concentration and absorbance as 




Figure 7. DM1 in DMSO standard curve from 11 uM to 700 uM. 
 
Equation 1.   𝐴𝑏𝑠	 = 	2.7907 ∗ [𝐷𝑀1] + 0.0406  
The r2 value is 0.98899. 
 
 
The difference in peak absorbances between AV and DM1 is crucial to being able 
to separate their combined absorbances for analysis of the conjugate. The spectra 
of both 1 mg/mL AV and 0.15 mM DM1 were taken separately from 200-400 nm. 




Figure 8. AV and DM1 spectra from 200-400 nm. Samples of pure solvent were 
subtracted from the individual samples to produce blank-corrected spectra. Peak 
absorption for 1 mg/mL AV occurred around 280 nm, and 0.15 mM DM1 peak 
absorption occurred at approximately 290 nm. 
 
The AV-DM1 conjugate was analyzed to determine the degree of drug loading. 
The absorbance at 288 nm of AV protein at approximately the same concentration 
of protein as the AV-DM1 conjugate was subtracted from the absorbance of AV-
DM1. The resulting value represents the contribution to the absorption of only the 
DM1 molecules. In the presented data in Figure 9, the peak absorbance 
contribution from the DM1 was 0.702 at 288 nm. Using the above standard curve 
equation, that correlates to approximately 0.24 mM DM1. The conjugate at 0.96 
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mg/mL is a concentration of 0.027 mM. So in this conjugation, the average drug-
protein ratio was 8.9 DM1 molecules per AV protein. 
 
 
Figure 9. AV-DM1 conjugate and unconjugated AV protein at approximately the 
same concentration 
 
The AV-DM1 conjugate was analyzed by SDS-PAGE on a 4-20% gradient 
denaturing gel. SDS-PAGE separates proteins based on size. An electric potential 
is applied to the gel causing proteins to migrate through the gel. Larger proteins, 
or proteins with additional modifications in this case, are impeded more relative 
to smaller, or unconjugated, proteins. As seen in Figure 10, the AV protein in the 
left-most lane migrated farther than the AV-DM1 conjugate. Also of note is the 
absence of any bands at multiples of 36 kDa (72, 108 kDa). This is confirmation 
that no AV-AV polymer products were made in the synthesis. 
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Figure 10. Picture of the SDS-PAGE gel. 5 uL of each the AV protein (1 mg/mL) 
and AV-DM1 conjugate (0.96 mg/mL) was denatured by boiling with 5 uL 
Laemmli sample buffer and 0.25 uL of 2-mercaptoethanol. Band migration was 
measured from bottom of the well to bottom of the band. The AV-DM1 conjugate 
band was measured to the bottom of the main upper band.  
 
Size can also be estimated from an SDS-PAGE gel. Protein kDa ladder standard 
migration distances are compared to the dye migration front and paired to the 
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logarithm of the protein size and plotted as seen in Figure 11. The migration front 
of the proteins/conjugates with unknown size can be measured and the size can be 
estimated with the plot made from the protein ladder standards. Once the AV-
DM1 conjugate and unconjugated AV sizes were estimated, the difference 
between them was divided by the combined weight of the linker and drug (about 1 
kDa) giving another estimate of the molecules of DM1 per protein. The error 
associated with SDS-PAGE molecular weight determination is usually within 5-
10%. A 5% error associated with the molecular weight of the conjugate is a 
difference of about 2 kDa, therefore, this method estimates the drug-protein ratio 
to be 6 ± 2 drug molecules per protein, within the range estimated by the 
absorption method described. 
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Figure 11. Plot of relative migration of protein standard ladder bands versus the 
logarithm of their size in kDa. This plot is used to estimate the size of unknown 
proteins run on the same gel. 
 
Equation 2.    𝑅𝑀	 = 	−0.5623 ∗ 𝑙𝑜𝑔(𝑘𝐷𝑎) + 1.4508	 





In Vitro Cytotoxicity  
 
In order to test the toxicity of the AV-DM1 conjugate, several cell lines were 
treated with many concentrations of the conjugate and compared to treatment with 
unconjugated DM1. The microtubule inhibiting mechanism of action of DM1 
kills cells by mitotic arrest. All five of the cell lines have documented doubling 
times of 22 or more hours. The standard 24-hour assay would not demonstrate the 
cytotoxic potential of the drug or conjugate simply because not all cells would 
have undergone a full cell cycle yet. To demonstrate this, EMT6 cells were used 
under similar conditions to the 72-hour cytotoxicity assays but treatment was 
halted after 24 hours and only six of the higher drug concentrations were tested. 
The results are shown in Figure 12. Neither the drug nor the conjugate showed 
significant toxicity to EMT6 cells over the 24-hour treatment time. 
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Figure 12. The 24-hour EMT6 cytotoxicity test. Neither of the treatments showed 
significant toxicity. Data is presented as mean ± SE (n = 6) Untreated cells 
determined 100% viability. 
 
The 72-hour assays proved to be much more effective against all five cell types. 
The effectiveness of the treatments was assessed by their EC50, the concentration 
of a drug were 50% effectiveness is reached in a given time period. The lower the 
EC50, the less of a drug is needed to achieve the half-maximal response. The 
EC50 is derived from the dose response curves by using the sum of squared 
differences to fit a sigmoidal regression of the form:  
 





Where V is the response (viability in this context), Max is the theoretical 
maximum response (100% viability), C is the concentration of drug, EC50 is the 
concentration of half-maximal effectiveness, and H is the Hill coefficient which 
describes how “steep” the curve is. 
The results for the breast cancer tumors are below: EMT6 in Figure 13, 4T1 in 
Figure 14, and MCF7 in Figure 15. Results for the P388 leukemia is in Figure 16 
and for the L1210 leukemia is in Figure 17. 
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Figure 13. Results for EMT6 murine breast cancer cell line cytotoxicity of the 
AV-DM1 conjugate and unconjugated DM1. The EC50 is 0.21 nM for the AV-
DM1 conjugate and 28 nM for unconjugated DM1. This is an increase in 
effectivity of 130x. Data is presented as mean ± SE (n = 6). 
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Figure 14. Results for 4T1 murine breast cancer cell line cytotoxicity of the AV-
DM1 conjugate and unconjugated DM1. The EC50 is 0.85 nM for the AV-DM1 
conjugate and 320 nM for unconjugated DM1. This is an increase in effectivity of 




Figure 15. Results for MCF7 human breast cancer cell line cytotoxicity of the 
AV-DM1 conjugate and unconjugated DM1. The EC50 is 0.52 nM for the AV-
DM1 conjugate and 473 nM for unconjugated DM1. This is an increase in 




Figure 16. Results for P388 murine leukemia cell line cytotoxicity of the AV-
DM1 conjugate and unconjugated DM1. The EC50 is 1.2 nM for the AV-DM1 
conjugate and 264 nM for unconjugated DM1. This is an increase in effectivity of 
221x. Data is presented as mean ± SE (n = 6). 
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Figure 17. Results for L1210 murine leukemia cell line cytotoxicity of the AV-
DM1 conjugate and unconjugated DM1. The EC50 is 0.26 nM for the AV-DM1 
conjugate and 93 nM for unconjugated DM1. This is an increase in effectivity of 




Brightfield and fluorescence imaging was done on P388 cells in order to 
qualitatively analyze both the viability and morphology of cells treated with the 
AV-DM1 conjugate and to demonstrate the binding specificity of the conjugate. A 
live-dead stain was used to indicate the viability of the cells. A membrane-
permeable non-fluorescent dye that is converted to a green fluorescent form in 
 39 
metabolically active cells stains for viable cells. Propidium iodide is membrane-
impermeable red fluorescent dye that binds DNA in cells with damaged 
membranes. The cells were treated for a period of only 3 hours. This was done in 
order to maintain the viability of cells in the EDTA-supplemented control group. 
EDTA chelates calcium ions which prevents efficient binding of the AV-DM1 
conjugate, but calcium is also necessary for long term cell viability. Only a small 
portion of cells in the treatment group would enter metaphase of the mitotic cycle 
in the 3 hour period, and even fewer would remain arrested there long enough to 
exhibit signs of apoptosis like membrane damage. Still, notably differences were 
seen between the EDTA and treatment groups in both brightfield and fluorescent 
microscope images. Brightfield images are shown in Figure 18 and Figure 19. 




Figure 18. Brightfield microscope image of P388 cells incubated for 3 hours with 
2 mM EDTA supplemented DMEM media and treated with calcium dependent 
AV-DM1 cytotoxic conjugate. Cell division has not been impaired and cells 
appear to be intact as indicated with green arrows in the figure. 
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Figure 19. Brightfield microscope image of P388 cells incubated for 3 hours with 
1.2 mM calcium DMEM media and treated with calcium dependent AV-DM1 
cytotoxic conjugate. Cell division has been slightly hindered, cells appear to not 
be as large as the EDTA treatment group. Some cells appear to be apoptotic with 




Figure 20. Live-Dead stained fluorescence microscope image of P388 cells 
incubated for 3 hours with 2 mM EDTA supplemented DMEM media and treated 
with calcium dependent AV-DM1 cytotoxic conjugate. Cell division has not been 
impaired and the vast majority of cells appear to be healthy and metabolically 
active with intact cell membranes. Dead cells appear red due to propidium iodide 




Figure 21. Live-Dead stained fluorescence microscope image of P388 cells 
incubated for 3 hours with 1.2 mM calcium DMEM media and treated with 
calcium dependent AV-DM1 cytotoxic conjugate. Cell division has been notably 
impaired compared to the EDTA treatment group and a greater portion of cells 
have compromised membranes, shown with white arrows. Dead cells appear red 







The conjugation and subsequent characterization of the AV-DM1 drug has many 
implications in the literature. The most commonly cited “ideal” drug ratio for 
antibody conjugates is three to five drugs per antibody. The logic that the more 
drugs that can be linked to a targeting protein, the more effective only holds up to 
a certain extent in mouse models. As the number of drug molecules on the protein 
increases, so does the overall hydrophobicity of the drug conjugate. Conjugates 
with higher hydrophobicity have shown higher rates of in vivo plasma clearance 
and less time in vascular circulation. Conjugates with eight conjugated 
hydrophobic drug molecules showed up to three times faster blood clearance than 
conjugates with four drugs per antibody. However, hydrophobicity is generally 
associated with more efficient uptake by the lymphatic system, not necessarily 
higher rates of degradation. More hydrophobic conjugates like antibody-DM1 
conjugates can have lymphatic residence half-lives of up to 7 days, though 
vascular circulation half-lives tend to be around 2-3 days [54-58].  
The conjugate that was synthesized had approximately eight drugs per 35 kDa 
protein. This is compared to Kadcyla (trastuzumab-emtansine) with about four 
drugs per 148 kDa protein [59]. The AV-DM1 conjugate proved very difficult to 
analyze with mass spectroscopy at least in part due to its high hydrophobicity. 
Although it proved effective in vitro, that success may be limited in follow-up 
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mouse tumor model experiments due to the potential for a high rate of clearance 
from the plasma and a short window to bind to and act on the tumor vasculature. 
The drug protein ratio may need to be lowered in order to effectively treat in vivo 
tumors. 
 
In Vitro Cytotoxicity 
 
The AV-DM1 conjugate showed remarkable increases in toxicity compared to the 
unconjugated DM1. The range of EC50s for unconjugated DM1 (~20-400 nM), 
matches well with literature values for a range of cell lineages. Although early 
publications on DM1 reported EC50s in the range of 1-10 pM, more recent 
literature has reported values from 1 nM to 1 uM [60, 61]. The AV-DM1 
conjugate also showed comparable activity to antibody-drug conjugates in the 
literature. AV-DM1 had a range from about  200 pM to 1.2 nM in the breast 
cancer and leukemia cells tested. Most literature reports in vitro EC50 values of 
100 pM to 10 nM [48, 62-63]. Kadcyla (trastuzumab-DM1) commonly has EC50 
values of about 3 nM in non-Hodgkins lymphoma [64],  huN901-DM1 has EC50 
values between 60 pM and 300 pM for various tumor lineages including 
colorectal cancer, lung cancers, and neuroblastoma [65]. 
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Chemotherapy has taken advantage of the narrow difference in toxicities of 
antineoplastic drugs between healthy cells and tumor cells. With the advent of 
targeted drugs, that difference can be widened, more potent and effective drugs 
can be used, and patients will not have to suffer as debilitating side effects. In 
pursuit of that goal, the AV-DM1 conjugate that has been synthesized, 
characterized, and tested has shown great potential as a cancer therapeutic. The 
synthesis is simple and quick with scalable chemistry. It is more potent by over 
100x than conventional chemotherapeutics. AV is highly selective in binding and 
is generalizable to many diverse types of solid tumor vasculatures and leukemias. 
However there are still many unanswered questions in regards to how well it will 
perform in vivo. The clearance and immune response to a highly conjugated small 
protein may be too high, and a lower drug protein ratio may be more useful for 
mouse models. Nevertheless, the preliminary work on the AV-DM1 conjugate 








With the clinical success shown by mainstream antibody-drug conjugates and 
especially by antibody-maytansinoid conjugates, there is every reason to move 
forward with investigating new approaches to make these treatments more widely 
available. Annexin V-DM1 has shown remarkable in vitro results comparable in 
specificity and toxicity to current antibody-drug conjugates in clinical use. 
Preclinical in vivo work is the next major step for the AV-DM1 conjugate, 
beginning with dosing studies. Studies involving conjugates using antibodies with 
a high drug to protein ratio (6-8) tended to show maximum tolerated doses of 
around 50-100 mg/kg [65]. More normal doses for treatment tend to be around 0.1 
- 0.5 mg/kg [64-66]. Eventually the AV-DM1 conjugate should be compared to 
current standard clinical treatments in leukemia and metastatic breast cancer, 
chlorambucil and doxorubicin respectively. Also of use may be a direct 
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72-hr Cytotoxicity Alamar Blue Metabolic Assay 
 For EMT6, 4T1, and MCF7 Cells 
Ben Southard - Revised 2/12/19 
 
Notes:  Growth media for EMT6 is Waymouth’s Medium (15% FBS, 1% 
Pen/Strep) 
 Growth media for 4T1 is RPMI-1640 (10% FBS, 1% Pen/Strep) 
 Growth media for MCF7 is EMEM (10% FBS, 1% Pen/Strep) 
 
1. In a 96-well plate, seed 5000 EMT6 cells in 200 uL of growth medium per 
well. Repeat in separate plates for 4T1 and MCF7 cells.  
2. A fourth plate will be used for blanks. 5000 cells per 200 uL of the 
respective growth medium will be seeded in six wells for each of the cell types. 
200 uL of each growth medium will also be added without cells into six more 
wells per cell type.  
3. Seeded cells should be incubated for 24 hours at 37ºC and 5% CO2 in 
order to recover, adhere, and begin growing. 
4. Prepare 150 uL each of 1 pM, 10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 
uM, 10 uM AV-DM1 conjugate in PBS by serial dilution. 
And prepare 150 uL each of 100 pM, 1 nM, 10 nM, 100 nM, 1 uM, 10 uM, 100 
uM and 1 mM unconjugated DM1 in PBS by serial dilution. 
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5. Aspirate and replace the media in all the plates with 180 uL of fresh 
media. 
6. Into each well of the three plates receiving treatment, add 20 uL of each 
drug in sextuplicute. Incubate all plates for 72 hours at 37ºC and 5% CO2. 
7. Aspirate and replace the media in all the plates with 180 uL of fresh 
media. 
8. Add 20 uL of Alamar Blue to every well of every plate and incubate for 2 
hours at 37ºC and 5% CO2. 
9. Read fluorescence: 530 nm excitation, 590 nm emission.  
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Annexin-DM1 Conjugation 
Ben Southard - Revised 2-28-19 
 
1. AV-SMCC preparation 
a. Completely dissolve 1.2 milligrams of Sulfo-SMCC in 200 uL of DI water 
i. This is a 100x molar ratio to 1 mg/mL annexin, about 10x molar ratio for 
the available lysine residues on annexin 
b. Add all of the Sulfo-SMCC solution to 1 mg of annexin 
c. Allow the mixture to react at 4 ºC for 1 hour 
2. AV-SMCC purification 
a. Dialyze overnight against 2 L of 20 mM phosphate buffer, pH 7.4 
i. Membrane MWCO should be between 1 and 10 kDa  
3. AV-SMCC-DM1 conjugation 
a. Completely dissolve 1.0 milligrams of DM1 in 150 uL of DMSO 
i. This is a 50x molar ratio to 1 mg/mL annexin, the degree of Sulfo-SMCC 
conjugation determines the number of available maleimide reaction sites 
b. Add all of the DM1 solution in DMSO to the prepared and dialyzed 
annexin-SMCC conjugate 
c. Allow the mixture to react at 4 ºC for 2 hours. 
4. AV-SMCC-DM1 purification 
a. Dialyze overnight against 2 L of 20 mM phosphate buffer, pH 7.4 
i. Membrane MWCO should be between 1 and 10 kDa  
5. Determine the product protein concentration by Bradford assay 
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a. [(Corrected OD at 595 nm) - .07154] / (.00048) = [protein] in ug/mL 
6. Determine the extent of DM1 conjugation by reading absorbance at 288 
nm of the conjugate and a blank of unconjugated annexin at the same 
concentration 
a. (Corrected OD at 288 nm) * (.3544) - .0123 = [DM1] in mM 
 
